Gene Therapy Market

Global Gene Therapy Market Size (2024 to 2032)

The global gene therapy market size is forecasted to grow at a remarkable CAGR of 30.1% from 2024 to 2032. The market size is predicted to be worth USD 73.89 billion by 2032 and USD 9.00 billion in 2024.

Current Scenario of the Global Gene Therapy Market

Gene therapy is an experimental method for treating or preventing illness by using genes. Gene therapies usually involve inserting a functional copy of a defective gene into the patient's cells. Genes are made up of DNA that contains the instructions for making proteins needed to function in the human body properly. Gene therapy is a treatment method that involves injecting DNA into a patient to cure genetic disorders. The new DNA has a working gene that can cure the symptoms of a disease that causes mutations. Repairing, repressing, and deleting defective genes are all part of gene therapy. Any neurological illnesses, such as muscular dystrophy and cystic fibrosis, and some hereditary conditions, tumors, and viral infections, may recover from this therapy. Since it helps correct the condition at the root DNA, this form of treatment is often referred to as a single-dose remedy. Several gene therapies for basic (single defect) and complicated genetic diseases have been developed over time. To date, ten gene therapies have been licensed (recent examples include Zolgensma, ZyntegloTM, and Collategene), and over a thousand product candidates are being tested in clinical trials around the world.

MARKET DRIVERS

The rapid R&D activities in this market are expected to lead to the commercialization of the global gene therapy market and further increase gene therapy popularity. Gene therapy is an essential area of the pharmaceutical industry and will grow in terms of market share in the future at a fast pace. Significant developments in molecular biology and cellular biology worldwide are primarily driving the growth of the global gene therapy market. The increase in population has led to a rise in chronic diseases, which is estimated to impact the market positively. The growing cases of cancer have fuelled the research and development being done for the market. The availability of reimbursements is another significant factor accelerating the growth rate of the market.

The development of technology due to increasing government initiatives has made it possible to commercialize the gene therapy market so that more and more private firms enter the market. The collaborations between private firms to develop gene therapy technology will increase the global gene therapy market growth during the forecast period. Gene therapy is also less risky than traditional methods, according to historical data.

The growth of the gene therapy market is regulated for various reasons, including the rapid use of synthetically engineered genes to cure different disorders, the ability to devise customized medicine, and an increase in gene therapy research and development, among others, fewer doses of medicines. It is a one-time treatment, and these factors are likely to create significant growth opportunities for the gene therapy market shortly. An increase in support and spending for gene therapy advances is projected to create substantial business gains for the companies operating in this space. For Instance, REGENXBIO, Inc. and Ultragenyx Pharmaceutical, Inc. partnered in March 2020 to use the NAV technology platform. The latter organization obtained a worldwide license to REGENXBIO's NAV AAV9 and AAV8 vectors to advance gene therapies for a rare metabolic disease as part of this collaboration.

MARKET RESTRAINTS

Lack of skilled professionals such as scientists and doctors, high cost of product development, stringent regulatory policies, side effects like unwanted immune responses, and concerns regarding the unethical use of gene therapy are the factors that could broadly impact the growth of the market of gene therapy in the coming years. Despite the rising prevalence of chronic diseases such as SMA and cancer, care remains prohibitively costly. The procedure is marketed as a single-dose therapy that corrects a hereditary deficiency in the patient's body. According to Novartis AG, a single dose of Kymriah, a cancer treatment drug, costs USD 475,000. The same drug is priced at USD 306,000 in Japan. High cost associated with the treatment; the budget challenge has reduced the healthcare expenditure. All these factors are expected to hamper the market growth to a small extent.

The complications associated with gene therapy are a major challenge to overcome for this market to shine further. Unwanted immune system response, a gene cannot be easily injected directly into the cells, newly released viruses may be seen as intruders by your immune system, which can target them, by focusing on the infection of the wrong cells infects you, and you become infected, the possibility of tumor formation. Despite this therapeutic and commercial promise, cell and gene therapy researchers face challenges in many areas, including allowing patient access, controlling the supply chain and manufacturing processes, and building a healthcare provider network, as with any modern, revolutionary, transformative technology.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Gene Therapy Market – By Vector Type

The viral vector had the largest market share in 2023 and is expected to grow reasonably during the forecast period. It is further divided into eight sub-segments. The key factor responsible for this increasing growth rate is the more accessible genetic modifications such as Lentivirus and Adeno-Associated Virus (AAV) to deliver gene therapy drugs. With the high accuracy in delivering the gene to the region of interest, the demand for adeno-associated viruses (AAV) as a platform for gene therapy delivery is expected to increase during the forecast period. Lentivirus in the viral vector segment is expected to grow at the highest rate among its peers during the forecast period. The main reason for the high growth in companies that offer an exclusive Lentivector platform to key gene therapy developers.

The non-viral sector is expected to grow at the fastest rate during the forecast period. Advancements in physicochemical approaches will drive the growth of this subsegment. These approaches include physical methods and chemical methods of the non-viral vector for gene therapies used during the clinical trials and treatment process. 

Global Gene Therapy Market – By Application

Based on the application, the oncological disorders segment contributed the highest revenue in 2023 and is expected to grow at a healthy rate during the forecast period. The main reason is the increasing number of cases of cancer around the world. The government has now contributed to the development by increasing regulatory approval of gene therapy for cancer. The improvement in technology is the key factor that will drive growth.

The cardiovascular disease sub-segment is expected to grow at the highest rate during the forecast period. The growing cases of cardiovascular diseases due to the prevalence of unhealthy lifestyles are the main reasons for growth. Improvement in healthcare facilities and rising awareness among people have positively impacted the development of the market.

The infectious disease segment is also expected to grow at a prominent rate during the forecast period. The main reason is the prevalence of coronavirus. The government's increase in funding to research institutes to develop the technology will drive the sub-segment growth.

REGIONAL ANALYSIS

Regionally, North America held the largest share of the global gene therapy market in 2023, with the growth rate expected to be high during the forecast period. An increase in the geriatric population and the prevalence of chronic diseases are significant growth contributing factors. The increased approvals from the Government bodies accepting the gene therapy process will motivate other notable players in the market.

Europe had the second largest market share and will grow at a promising rate during the forecast period, mainly due to increased chronic diseases and improved healthcare facilities in European countries.

The Asia Pacific is expected to grow at the fastest rate during the forecast period. The increase in population in India and China is the major contributing factor to the growth rate. The Asia Pacific market for gene therapy is estimated to witness a double-digit growth rate over the forecast period. Increasing adoption by the government and rising approvals will help the market to grow.

KEY MARKET PARTICIPANTS

Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc. are the dominating companies in the global gene therapy market.

KEY MARKET HAPPENINGS

• Biogen (US) acquired Nightstar Therapeutics (UK) in June 2019 to expand its business reach.
• Amgen (US) partnered with the University of Texas MD Anderson Cancer Center (US) in June 2018 to create several early-stage oncology therapies.
• The FDA approved ZOLGENSMA in May 2019 by Novartis AG (Switzerland).
• In November 2020, Scientists created a novel gene therapy strategy that can one day cure an eye condition that causes irreversible vision loss and affects thousands of people worldwide.

DETAILED SEGMENTATION OF THE GLOBAL GENE THERAPY MARKET INCLUDED IN THIS REPORT

This market research report on the global gene therapy market has been segmented and sub-segmented based on vector type, application, and region.

By Vector Type

• Viral vector
  • Retroviruses
  • Lentiviruses
  • Adenoviruses
  • Adeno-associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others
• Non-viral vector
  • Naked/Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

By Application

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious disease
• Other Diseases

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa